Summary:
A Variable Length Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Triple-combination of Budesonide/Glycopyrronium/Formoterol Fumarate in Adult and Adolescent Participants with Inadequately Controlled Asthma
Qualified Participants Must:
• 12-80 years of age
•
Diagnosed with Asthma for 1 year or more
Qualified Participants May Receive:
Participants will be compensated $75 per completed visit for time and travel